Because VT1021 does not target a specific mutation in tumor cells but rather induces TSP-1 that inhibits tumor growth via binding to CD36 and CD47 on the surface of tumor cells, it is critical to identify patients that express sufficient levels of these receptors to maximize its anti-tumor activity. This evidence concerns the gene CD47 and neoplasm.